The Lovesac Company Announces Fourth Quarter and Fiscal 2026 Conference Call Date STAMFORD, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand, today announced that its fourth quarter and fiscal 2026 financial results will be released before market open on Thursday, March 26, 2026. The Company will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results. Investors and analysts interested in participating in the call are invited to dial 877-407-3982 (internatio...
Newtek Bank, N.A. Introduces the Newtek Seven Day Business Loan™ BOCA RATON, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (NASDAQ: NEWT) (“NewtekOne”) announced that its bank subsidiary, Newtek Bank, National Association (the “Bank”), launched the Newtek Seven Day Business Loan™: business loans of up to $350,000 funded to approved borrowers within seven days of a complete loan application. The Newtek Seven Day Business Loan is structured over a ten-year repayment period, with no balloon payment risk, and a total borrowing cost – including interest and fees – that we believe is...
Xos Announces Production Rollout of Vehicle-to-Grid Capability Across Its Full Commercial Electric Vehicle and Energy Solutions Portfolio V2G production scheduled for April 2026 on one of North America’s largest school bus platforms, enabling fleets to return energy to the grid and offset operating costsBidirectional technology roadmap will extend across Xos’s product portfolio LOS ANGELES, March 09, 2026 (GLOBE NEWSWIRE) -- Xos, Inc. (NASDAQ: XOS) (“Xos” or the “Company”), a leader in electric commercial vehicles and mobile charging solutions, today announced V2G (Vehicle-to-Grid) produ...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to one new employee. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as...
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the Leerink Partners Global Healthcare Conference in Miami, FL on Tuesday, March 10, 2025 at 1:00 p.m. ET. The webcast of the presentation will be accessible or by visiting the "Eve...
Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01 STAFFORD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on the increased patient screen rate in FLAMINGO-01. FLAMINGO-01 Annual Patient Screen Rate Increases to Over 800 Patients per Year Over the past 6 months, the Comp...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.